Sentiment Summary
Recent Events
Final dividend of HK$0.771 per share for the year 2025. The ex-dividend date is June 10, 2026, with payment on July 27, 2026 scheduled.
Final dividend of 0.75 yuan per share for fiscal year 2025 with an ex-dividend date of May 12, 2026 (Medium importance as dividend payouts typically support stock price) scheduled.
Robert J. Gaudette is scheduled to become Chief Executive Officer on 2026-04-30, succeeding Lawrence Coben, as part of a leadership succession plan announced on 2026-01-07. The stock dropped 5% on the announcement. scheduled
Illinois Tool Works is expected to announce its Q1 2026 earnings results on or around April 29, 2026; high importance is estimated due to the significant impact of quarterly earnings on stock price, scheduled.
Mastercard's Q1 2026 earnings release on 2026-04-23 scheduled.
Lam Research's Q3 2026 earnings report is scheduled for April 22, 2026. Analysts forecast an EPS of approximately $1.33-$1.35, which would be an increase year-over-year; a low impact is estimated until the actual results are released, scheduled.
Annual General Meeting for FY2025 and class shareholder meetings for A and H shares scheduled for April 21, 2026, to approve the profit distribution plan and amend the Articles of Association; neutral impact expected as these are routine administrative meetings scheduled
Quarterly dividend ex-date of $1.61 per share on March 31, 2026, announced on February 13, 2026, scheduled.
Presented positive Phase 3b clinical trial data showing that the combination of its drugs Taltz and Zepbound was superior to Taltz alone for treating adults with active psoriatic arthritis and obesity. Analysts estimate a price impact of ≥1% due to positive clinical results, estimated.
Fiscal year 2025 results announcement on March 27, 2026, with revenue rising 35% to 9.18 billion yuan and attributable profit increasing to 1.10 billion yuan (High importance due to projected 35% revenue growth) expected.
Reports surfaced on 2026-03-27 that Mastercard is exploring a sale of its real-time payments unit.
Announced full-year 2025 financial results on March 26, 2026. Revenue increased by 30.0% YoY to RMB 5.05 billion, and net profit rose by 36.8% YoY to RMB 1.205 billion. The results exceeded market expectations, and the stock price surged nearly 13% in early trading the following day.
The Federal Trade Commission (FTC) sent warning letters on 2026-03-26 to the CEOs of Mastercard regarding the potential for 'debanking' customers.
Kuaishou announced its Q4 and full-year 2025 financial results on March 25, 2026. Full-year 2025 adjusted net profit increased by 16.5% year-over-year to RMB 20.6 billion, and revenue grew 12.5% to RMB 142.8 billion. A price impact of 10% or more is expected.
Full-year 2025 results announced on March 25, 2026, reporting a 13.3% revenue increase to RMB 80.22 billion and a 13.9% profit increase with a recommended dividend of HKD 1.08; High importance reflects an estimated >10% price impact, expected
CSPC Pharmaceutical Group announced its FY2025 results on 2026-03-25, reporting a 10.4% YoY decrease in revenue to RMB 26.01 billion and a 10.3% YoY decrease in net profit to RMB 3.88 billion. A final dividend of HKD 0.15 per share was proposed.
Announced FY2025 results: Revenue of $3.42B (down 10.4% YoY), but profit attributable to owners rose 1.5% to $404M. A final dividend of 4.1446 US cents per share was proposed. The results were seen as positive, with the share price reportedly rising afterward.
The Board of Directors adopted the '2026 Share Award Plan' on 2026-03-25 to provide incentives to selected participants. The total number of shares to be purchased under the plan will not exceed 3% of the total issued shares.